1009120-03-9

Basic information

• Product Name: (S)-2-(Methoxycarbonylamino)-2-(tetrahydro-2H-pyran-4-yl)ethanoic acid
• Synonyms: (S)-2-(Methoxycarbonylamino)-2-(tetrahydro-2H-pyran-4-yl)ethanoic acid;METHYL N-METHOXYCARBONYL-2-(OXAN-4-YL)-L-GLYCINATE
• CAS NO: 1009120-03-9
• Molecular Formula: C₉H₁₅NO₅
• Molecular Weight: 217.2191
• Mol File: 1009120-03-9.mol
• Article Data: 24

Chemical Properties

• Boiling Point: 409.9±20.0 °C(Predicted)
• Appearance: /
• Density: 1 +-.0.06 g/cm3(Predicted)
• PKA: 4.26±0.10(Predicted)
• CAS DataBase Reference: (S)-2-(Methoxycarbonylamino)-2-(tetrahydro-2H-pyran-4-yl)ethanoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-2-(Methoxycarbonylamino)-2-(tetrahydro-2H-pyran-4-yl)ethanoic acid(1009120-03-9)
• EPA Substance Registry System: (S)-2-(Methoxycarbonylamino)-2-(tetrahydro-2H-pyran-4-yl)ethanoic acid(1009120-03-9)

Safety Data

• Hazardous Substances Data: 1009120-03-9(Hazardous Substances Data)

Usage

Description

(S)-2-(Methoxycarbonylamino)-2-(tetrahydro-2H-pyran-4-yl)ethanoic acid is a chemical compound characterized by its molecular formula C11H17NO5. It is an amino acid derivative featuring a tetrahydropyran group, a type of cyclic ether, which endows it with unique structural features. (S)-2-(Methoxycarbonylamino)-2-(tetrahydro-2H-pyran-4-yl)ethanoic acid serves as a versatile building block for the synthesis of a variety of pharmaceuticals and organic molecules, and it holds promise in the fields of medicinal chemistry and drug discovery.

Uses

Used in Pharmaceutical Synthesis:
(S)-2-(Methoxycarbonylamino)-2-(tetrahydro-2H-pyran-4-yl)ethanoic acid is used as a key intermediate in the synthesis of pharmaceuticals for its ability to contribute to the formation of complex molecular structures that can exhibit therapeutic properties.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, (S)-2-(Methoxycarbonylamino)-2-(tetrahydro-2H-pyran-4-yl)ethanoic acid is utilized as a structural component in the design and development of new drugs, potentially leading to innovative treatments for various diseases.
Used in Drug Discovery:
(S)-2-(Methoxycarbonylamino)-2-(tetrahydro-2H-pyran-4-yl)ethanoic acid is employed in drug discovery processes to explore its potential as a precursor to new bioactive molecules, which may offer novel mechanisms of action or improved pharmacokinetic profiles.
While the specific applications and properties of (S)-2-(Methoxycarbonylamino)-2-(tetrahydro-2H-pyran-4-yl)ethanoic acid are still under investigation, its unique structure suggests a broad range of possibilities across different industries, particularly in healthcare and pharmaceutical development. Further research is essential to fully realize its potential and optimize its use in these areas.

Upstream product

• 368866-32-4 (S)-pyranylglycine methyl ester 
• 894789-28-7 (S)-N-Cbz-pyranyl glycine methyl ester 
• 477584-90-0 methyl 2-(((benzyloxy)carbonyl)amino)-2-(dihydro-2H-pyran-4(3H)-ylidene)acetate 
• 29943-42-8 Tetrahydro-4H-pyran-4-one 
• 1257239-30-7 C₁₀H₁₇NO₅ 
• 811842-25-8 (S)-2-amino-2-(tetrahydro-2 H-pyran-4-yl)acetic acid 
• 79-22-1 methyl chloroformate 

Downstream Products

• 1433280-54-6 [(S)-2-{(2S,4S)-2-[4-(4-bromo-phenyl)-1H-imidazol-2-yl]-4-methyl-pyrrolidin-1-yl}-2-oxo-1-(tetrahydropyran-4-yl)-ethyl]-carbamic acid methyl ester 
• 1433280-55-7 [(S)-2-((2S,4S)-4-methyl-2-{4-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-phenyl]-1H-imidazol-2-yl}-pyrrolidin-1-yl)-2-oxo-1-(tetrahydro-pyran-4-yl)-ethyl]-carbamic acid methyl ester 
• 1377604-13-1 methyl (S)-2-((1R,3S,4S)-3-(7-(4-(2-((S)-1-((S)-2-(methoxycarbonylamino)-3-methylbutanoyl)pyrroIidin-2-yl)-1H-imidazol-5-yl)phenyl)-1H-naphtho[1,2-d]imidazoI-2-yl)-2-azabicydo[2.2.1]heptan-2-yl)-2-oxo-1-(tetrahydro-2H-pyran-4-yl)ethylcarbamate 
• 1250941-34-4 dimethyl (1,2-ethynediylbis(3,1-phenylene-1H-imidazote-4,2-diyl(2S)-2,1-pyrrolidinediyl((1S)-0.122-oxo-1-(tetrahydro-2H-pyran-4-yl)-2,1-ethanediyl)))biscarbamate 

Relevant articles and documents

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

HEPATITIS C VIRUS INHIBITORS

The invention provides compounds of formulas (I) or (II): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.

HEPATITIS C VIRUS INHIBITORS

The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.